Deciphera Pharmaceuticals Inc 's ROA from the first quarter of 2024 to the first quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Deciphera Pharmaceuticals Inc 's ROA in the first quarter of 2024?
Deciphera Pharmaceuticals Inc recorded a cumulative net loss of $-190 million during 12 months ending in the first quarter of 2024, resulting in a negative return on assets (ROA) of -42.76%.

However, within the Healthcare sector 564 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2024 quarter, so far to 4191, from total ROA ranking in the fourth quarter of 2023 at 4797.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter
Y / Y Total Assets Change	-23.95 %	6.41 %	6.21 %	1.62 %	47.39 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-190	-195	-194	-187	-182
Return On Assets (TTM)	-42.76 %	-40.94 %	-41.26 %	-40.45 %	-39.43 %
DCPH's Total Ranking	# 4191	# 4797	# 4275	# 4350	# 4450
Total Assets (TTM) in million	392	447	466	476	515
Seq. Total Assets Change	-12.36 %	-4.1 %	-2.03 %	-7.64 %	22.63 %
Seq. Net Income Change	-	-	-	-	-

DCPH's 5 Years Annual ROA >> Back to DCPH Management Effectiveness >> Compare DCPH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 237
Sector	# 565
Overall	# 4119

Return On Assets Statistics
High	Average	Low
-20.24 %	-39.44 %	-62.11 %
(Mar 31 2019)		(Mar 31 2022)

Financial Statements
Deciphera Pharmaceuticals Inc 's Assets	$ 392 million	DCPH's Balance sheet
Deciphera Pharmaceuticals Inc 's Income	$ -45 million	Quarterly DCPH's Income Statement
DCPH's Income by Division		See DCPH's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	5.24 %	7.01 %	-35.21 %	0.8 %	756.2 %
Total Assets in million	442	420	393	606	601
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-195	-179	-300	-266	-192
Annual Return On Assets	-44.08 %	-42.58 %	-76.39 %	-43.97 %	-31.98 %

DCPH's 5 Years Annual ROA >> Back to DCPH Management Effectiveness >> Compare DCPH ROA to its Competitors

More Return On Assets Ratios
DCPH's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DCPH's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DCPH's Competitors
Subscribers only: Roa for Deciphera Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for DCPH's Customers

You may also want to know
DCPH's Roi	DCPH's Inventory Turnover Ratio	DCPH's Growth Rates	DCPH's Dividend Comparisons
	DCPH's Profitability Ratios	DCPH's Asset Turnover Ratio	DCPH's Dividend Growth
DCPH's Roe	DCPH's Valuation Ratios	DCPH's Financial Strength Ratios	DCPH's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2024, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:32:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.